The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | Novel agents in development for multiple myeloma: CELMoDs, antibody-drug conjugates, and peptides
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses novel agents in development for multiple myeloma (MM). He highlights cereblon E3 ligase modulatory drugs (CELMoDs), antibody-drug conjugates, peptide drugs, and emerging immune-targeting approaches. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Consultancy, Honoraria, Research Funding; Janssen: Honoraria; BMS: Honoraria; AbbVie: Honoraria; Roche: Honoraria; University College London Hospitals NHS Foundation Trus: Current Employment. Gironella: Janssen: Consultancy, Honoraria; GSK: Consultancy.
